

Mutations in *PPCS*, encoding phosphopantothenoylcystein synthetase, cause autosomal recessive dilated cardiomyopathy

Arcangela Luso<sup>1,2,3,24</sup>, Marit Wiersma<sup>4, 24</sup>, Hans-Joachim Schüller<sup>5, 24</sup>, Ben Pode-Shakked<sup>6,7,8, 24</sup>, Dina Marek-Yagel<sup>6,8, 24</sup>, Mathias Grigat<sup>5</sup>, Thomas Schwarzmayr<sup>1,2</sup>, Riccardo Berutti<sup>2</sup>, Bader Alhaddad<sup>1</sup>, Bart Kanon<sup>9</sup>, Nicola A. Grzeschik<sup>9</sup>, Jürgen G. Okun<sup>10</sup>, Zeev Perles<sup>11</sup>, Yishay Salem<sup>8,12</sup>, Ortal Barel<sup>8,13</sup>, Amir Vardi<sup>8,14</sup>, Marina Rubinshtein<sup>18</sup>, Tal Tirosh<sup>8,12</sup>, Gal Dubnov-Raz<sup>8,15</sup>, Ana C Messias<sup>16,17</sup>, Caterina Terrile<sup>1,2</sup>, Iris Barshack<sup>8,19</sup>, Alex Volkov<sup>8,19</sup>, Camilla Avivi<sup>8,19</sup>, Eran Eyal<sup>13</sup>, Elisa Mastantuono<sup>1,2</sup>, Muhamad Kumbar<sup>20</sup>, Shachar Abudi<sup>6,8</sup>, Matthias Braunisch<sup>1,21</sup>, Tim M Strom<sup>1,2</sup>, Thomas Meitinger<sup>1,2,3</sup>, Georg F Hoffmann<sup>10</sup>, Holger Prokisch<sup>1,2,25</sup>, Tobias B Haack<sup>1,2,22</sup>, Bianca JJM Brundel<sup>4</sup>, Dorothea Haas<sup>10,25,\*</sup>, Ody CM Sibon<sup>9,25</sup>, Yair Anikster<sup>6,8,23,25,\*</sup>

1. Institute of Human Genetics, Technische Universität München, 81675 Munich, Germany.
2. Institute of Human Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany.
3. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, 80802 Munich, Germany.
4. Department of Physiology, Amsterdam Cardiovascular Sciences, VUmc, 1081 HZ Amsterdam, The Netherlands.
5. Institute für Genetik und Funktionelle Genomforschung, Ernst-Moritz-Arndt Universität, 17489 Greifswald, Germany.
6. Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52621 Tel-Hashomer, Israel.
7. The Dr. Pinchas Borenstein Talpiot Medical Leadership Program, Sheba Medical Center, 52621 Tel-Hashomer, Israel.
8. Sackler Faculty of Medicine, 6997801 Tel-Aviv University, Tel-Aviv, Israel.

9. Department of Cell Biology, University of Groningen, University Medical Center Groningen, 9713 AV Groningen, The Netherlands.
10. Division of Neuropediatrics and Metabolic Disease, University Children's Hospital, 69120 Heidelberg, Germany.
11. Department of Pediatric Cardiology, Hadassah-Hebrew University Medical Center, 91120 Jerusalem, Israel.
12. Pediatric Cardiology Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52621 Tel-Hashomer, Ramat Gan, Israel.
13. Sheba Cancer Research Center, Sheba Medical Center, 52621 Tel-Hashomer, Israel.
14. Department of Pediatric Cardiac Intensive Care, Edmond Safra International Congenital Heart Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52621 Tel-Hashomer, Israel.
15. Exercise, Nutrition and Lifestyle clinic, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52621 Tel-Hashomer, Israel.
16. Institute of Structural Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany.
17. Center for Integrated Protein Science Munich at Biomolecular NMR Spectroscopy, Department Chemistry, Technische Universität München, 85747 Garching, Germany.
18. Department of Pediatric Critical Care Medicine, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, 52621 Tel-Hashomer, Israel.
19. Department of Pathology, Sheba Medical Center, 52621 Tel-Hashomer, Israel.
20. Clalit Health Services, 93133 Jerusalem, Israel.
21. Department of Nephrology, Klinikum rechts der Isar, Technische Universität München, 81675 Munich, Germany.
22. Institute of Medical Genetics and Applied Genomics, University of Tübingen, 72076 Tübingen, Germany

23.The Wohl Institute for Translational Medicine, Sheba Medical Center, 52621 Tel-Hashomer, Israel.

24.These authors contributed equally to the manuscript.

25.These authors contributed equally to the manuscript.

## **ABSTRACT**

Coenzyme A (CoA) is an essential metabolic cofactor used by around 4% of cellular enzymes. Its role is to carry and transfer acetyl and acyl groups to other molecules. Cells can synthesize CoA *de novo* from vitamin B5 (pantothenate) through five consecutive enzymatic steps. Phosphopantothenoylcystein synthetase (*PPCS*) catalyzes the second step of the pathway during which phosphopantothenate reacts with ATP and cysteine to form phosphopantothenoylcystein. Inborn errors of CoA biosynthesis have been implicated in Neurodegeneration with Brain Iron Accumulation (NBIA), a group of rare neurological disorders characterized by accumulation of iron in the basal ganglia and progressive neurodegeneration. Exome sequencing in five individuals from two unrelated families presenting with dilated cardiomyopathy revealed biallelic mutations in *PPCS*, linking CoA synthesis with a cardiac phenotype. Studies in yeast and fruit flies confirmed the pathogenicity of identified mutations. Biochemical analysis revealed a decrease in CoA levels in fibroblasts of all affected individuals. CoA biosynthesis can occur with pantethine as a source independent from *PPCS*, suggesting pantethine as targeted treatment for the affected individuals still alive.

## **KEYWORDS**

*PPCS*; Coenzyme A; Dilated cardiomyopathy; Pantethine treatment.

## **INTRODUCTION**

The pathway of CoA *de novo* biosynthesis from vitamin B5 is conserved in Eukaryotes and Prokaryotes and consists of five consecutive enzymatic steps. Dysfunction of two of the involved enzymes, *PANK2* (OMIM: 606157) and *COASY* (OMIM: 609855), has been identified as a cause of autosomal recessive Neurodegeneration with Brain Iron Accumulation (NBIA). Mutations in *PANK2*, encoding pantothenate

kinase 2 necessary for the first enzymatic step of CoA biosynthesis, represent a major cause of NBIA and are detected in about half of cases with the eye-of-the-tiger sign, a pathognomonic finding on brain MRI<sup>1</sup>. Mutations in *COASY*, encoding bifunctional CoA synthase, catalyzing the last two steps, have so far been identified in only five patients with basal ganglia lesions<sup>2-5</sup>. To our knowledge mutations in *PPCS* (OMIM: 609853), encoding phosphopantothenoylcystein synthetase have so far not been associated with human diseases. *PPCS* catalyzes the second enzymatic step during which phosphopantothenate reacts with ATP (or CTP) and with cysteine to form phosphopantothenoylcystein (Figure 1). The yeast orthologue *YIL083C/CAB2* (*yPPCS*) is an essential gene with haploid *CAB2* mutants being non-viable even after medium supplementation with fatty acids<sup>6</sup>. In *Drosophila melanogaster* *CG5629* (*dPPCS*) is required for tissue morphogenesis during oogenesis<sup>7</sup>. Null mutants for *dPPCS* are lethal at the first instar larvae, while hypomorphic alleles exhibit locomotor defects, altered lipid homeostasis, and reduced life span<sup>8</sup>. In human there are two consistently annotated isoforms of *PPCS* (Figure 2A). A canonical isoform (NM\_024664.3) encoding a protein of 311 aminoacids, and a shorter isoform (NM\_001077447.2) encoding a protein of 138 aminoacids. The two isoforms share the C-terminal region. According to public databases both isoforms are ubiquitously expressed (The Human Protein Atlas), although with tissue-specific differences (GTEx Portal). Here we report on the identification of biallelic mutations in *PPCS* in five individuals from two unrelated families presenting with severe dilated cardiomyopathy (Figure 2B). Clinical findings are summarized in Table 1.

## **SUBJECTS AND METHODS**

Informed written consent to participate in the study was obtained from all individuals or their parents in the case of minors. The study was approved by the ethics committee of the Technische Universität München (Munich, Germany), and the Institutional Review Board of the Sheba Medical Center (Tel Aviv, Israel).

## **Subjects**

Family A, individual II.2, born to healthy non-consanguineous parents of German descent, presented in the first few hours after birth with an acute life-threatening event followed by a tonic seizure. She showed minor dysmorphic features including cutis laxa, abnormally placed thumbs, abnormal dermatoglyphics, hypoplastic toe nails and additional findings. She experienced a complicated course of illness requiring several hospitalizations. An extensive evaluation revealed severe dilated cardiomyopathy, pulmonary arterial hypertension, suspected pituitary dysfunction and muscular hypotonia. Unfortunately, she succumbed to multi-organ failure, at three months of age.

Family B is a multiplex consanguineous family of Arab-Muslim descent. The parents are reportedly healthy and are first-degree cousins. Four out of eight siblings exhibited dilated cardiomyopathy of varying severity, without apparent extracardiac manifestations. Among the four affected siblings, two (individuals IV.1 and IV.4) showed a milder form of dilated cardiomyopathy, enabling a degree of regular daily activities. The other two siblings (individuals IV.5 and IV.8) showed a severe form of dilated cardiomyopathy, fatal in early childhood (three years of age). The four unaffected siblings are asymptomatic and healthy. The echocardiograms of the unaffected siblings and their parents were normal. Detailed clinical case reports are available in the Supplemental Data (Case Reports) Demographic, clinical and molecular findings are summarized in Table 1.

## **Whole Exome Sequencing and Sanger Sequencing**

We performed exome sequencing at two centers (Family A in Munich, Family B in Tel Aviv). In affected individuals of families A and B, coding regions were enriched with a SureSelect Human All Exon V5 Kit (Agilent) and sequenced as 100-bp paired-end runs on an Illumina HiSeq 2500. Reads were aligned to the human reference genome (UCSC Genome Browser, build hg19) with the Burrows-Wheeler Aligner

(v.0.7.5a). Single-nucleotide variants and small insertions and deletions (indels) were detected by SAMtools (v.0.1.19). Sanger sequencing was used to confirm the identified mutations and test the carrier status of unaffected family members using the following primer pairs: F-5' TGGACAACCTTCAGCAGCG 3' / R-5' ACAGATGCAAATAGTCCGCC 3' and F-5' CCCTTACCTCCTGCTTACCC3' / R-5' ACAGATGCAGAAAGGCCATC 3' for family A, and F-5'TTCCATGAGATTGACCTGGTA3' / R-5' CAAATGCCAAACCATATTTGC3' for family B.

### **Bioinformatic Analysis**

Structural files of the human *PPCS*<sup>9</sup>(PDB 1P9O) and of the orthologous *E. coli* gene<sup>10</sup> (PDB 1U7W) were downloaded from the protein data bank (PDB)<sup>11</sup>. Sequence alignment to detect the evolutionary relation between the enzymes was done using psi-blast<sup>12</sup>. Structural alignment between proteins was done using triangular match<sup>13</sup>. Initial analysis of the variant location was done using G23D<sup>14</sup>. Structural images were created using UCSF Chimera<sup>15</sup>. Calculation of solvent accessible area of residues at the variant positions was done using Getarea<sup>16</sup>. A variety of programs for assessment of function and stability changes following the mutations were applied and are listed in Table S1 including the URL and reference. Conservation analysis and mapping of conservation scores on the structure were done using ConSurf<sup>17</sup>. Prediction of binding site based on structural data was done using the Coach algorithm<sup>18</sup> in the I-Tasser website<sup>19</sup>

### **RNA Extraction, RT-PCR, Cloning and Mutagenesis of PPCS**

Total RNA was isolated from fibroblasts of healthy donors (80% confluence) with the AllPrep RNA Kit (Qiagen). RNA quantity was measured with the Nanodrop instrument (Nanodrop Technologies). For the RT-PCR, one microgram of RNA was reverse transcribed with M-MLV reverse transcriptase (Promega, GmbH) and oligo dT. *PPCS* (NM\_024664.3) coding region was amplified with Thermo-Start Taq DNA

Polymerase (ABgene, Epsom, UK) and primers F-5'CACGATGGCGGAAATGGATCCGGT3' and R-5'TCAGTTTCTGTACCTATAAAAGCTGTG3'. Wild-type *PPCS* retaining the endogenous terminal stop-codon was cloned in the vector pLenti6.3/V5™-TOPO (Invitrogen).

The *PPCS* variants were obtained by site-directed mutagenesis of the cloned *PPCS* ORF using the kit QuikChange II Site-Directed Mutagenesis (Stratagene) and the primer pairs:

F-5' TTACCTGGCTGCGCCTGTGTCAGATTCTATG 3' / R-5' CATAGAAATCTGACACAGGCGCAGCCAGGTAA 3' to introduce the change 538G>C, F-5' TGTCCGCTCTGCGGCTTTCGGGCTTGC 3' / R-5' GCAAGCCCGAAAGCCGAGAGCGGACA 3' for the change 320\_334del, and F-5' TTTCTTTAAGTTGGTGACTGACCCCGCCATT 3' / R-5' AATGGCGGGGTCAGTCACCAACTTAAAGGAAA 3' for the change 698A>T. The following plasmids were hence generated: *PPCS*\_wild type \_pLenti6.3, *PPCS*\_c.320\_334del pLenti6.3, *PPCS*\_c.538G>C pLenti6.3, and *PPCS*\_c.698A>T pLenti6.3.

### **Complementation of *PPCS*-deficient Fibroblast Cell Line**

The fibroblast cell line derived from individual II.2 of family A was complemented with the wild type copy of *PPCS* cloned in the pLenti6.3/V5™-TOPO (Invitrogen) as described in <sup>20</sup>.

### **Yeast Strain and Plasmids**

#### **Construction of Yeast Expression Plasmids**

*PPCS*\_wild type pLenti6.3, *PPCS*\_c.320\_334del pLenti6.3, *PPCS*\_c.538G>C pLenti6.3, and *PPCS*\_c.698A>T pLenti6.3 were used as templates to amplify cDNAs of the human *PPCS* (*hPPCS*) variants. The amplification was performed with a proofreading-competent Phusion DNA polymerase (ThermoFisher) using primers *PPCS*-XbaIStart (5' GATCTCTAGAAAAATGGCGGAAATGGATCCGGT 3') and *PPCS*-SallIStop (5' GATCGTCTGACTCAGTTTCTGTACCTATAAAAG 3'). PCR fragments were cleaved with XbaI and Sall and cloned into the single-copy expression yeast plasmid p415-MET25 <sup>21</sup>. p415-MET25 contains *LEU2* as a

selection marker and *MET25* as promoter to activate heterologous genes. *MET25* is a promoter of intermediary strength typical for most yeast genes with a metabolic function while extreme overexpression of heterologous genes is prevented.

We thus obtained plasmids pMET-PPCS-WT (*hPPCS*, wild-type), pMET-PPCS-320\_334del (*hPPCS* deletion allele 320\_334), pMET-PPCS-538G>C (*hPPCS* 538G>C missense variant) and pMET-PPCS-698A>T (*hPPCS* 698A>T missense variant).

### **Plasmid Shuffling**

Single-copy plasmid pGE11 containing *yPPCS* together with *URA3* as a selection marker was transformed into *S. cerevisiae* wild-type strain JS91.15-23 (*ura3 leu2 trp1 his3 CAB2*). Subsequently the chromosomal *yPPCS* gene was deleted by using the gene disruption cassette from plasmid pJO9 (*cab2Δ::HIS3*). After selecting for His-prototrophic transformants, strain MGY9 was obtained which is viable due to the plasmid copy of *yPPCS* compensating for the loss of chromosomal *yPPCS*. The authenticity of the desired genomic alteration was verified by PCR, using gene-specific primers (not shown).

*S. cerevisiae* strain MGY9 was hence transformed with plasmids pMET-PPCS-WT, pMET-PPCS-320\_334del, pMET-PPCS-538G>C, and pMET-PPCS-698A>T, together with the empty vector p415-MET25 (negative control) and pGE12 (authentic *CAB2* as a positive control). Dilutions of Leu-prototrophic transformants were subsequently spotted on a medium containing 5-Fluoroorotic acid (5-FOA) which allows counter-selection of plasmids containing *URA3* as a genetic marker. Thus, plasmid pGE11 (*URA3 CAB2*) is lost and growth is possible only when *LEU2*-containing plasmids compensate for the loss of pGE11.

*Saccharomyces cerevisiae* strain:

MGY9 ( $\alpha$  *ura3 leu2 trp1 his3 cab2Δ::HIS3 [ARS CEN URA3 CAB2]*)

Plasmids:

pJO9 (*cab2Δ::HIS3* deletion cassette)

pGE11 (*ARS CEN URA3 CAB2*)

pGE12 (*ARS CEN LEU2 CAB2*)

p415-MET25 (*ARS CEN LEU2 MET25<sub>Prom.</sub>*)

pMET-PPCS-WT (*ARS CEN LEU2 MET25<sub>Prom.</sub>-hPPCS*)

pMET-PPCS-320\_334del (*ARS CEN LEU2 MET25<sub>Prom.</sub>-hPPCS 320\_334del*)

pMET-PPCS-538G\_C (*ARS CEN LEU2 MET25<sub>Prom.</sub>-hPPCS 538G>C*)

pMET-PPCS-698A\_T (*ARS CEN LEU2 MET25<sub>Prom.</sub>-hPPCS 698A>T*)

### **Western Blotting**

Analysis of PPCS protein level was performed on whole cellular lysate under denaturing conditions and proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; Lonza, PAGER EX Gels). The analysis of PPCS dimer formation was performed on whole cellular lysate under non-reducing non-denaturing conditions and separated by blue native polyacrylamide gel electrophoresis (BN-PAGE; ThermoFisher, NativePAGE Novex Bis-Tris Gel System). Denaturing and native gels were blotted onto PVDF membrane (GE-Healthcare) for subsequent incubation with primary antibodies and probing with appropriate secondary antibodies. Chemiluminescence was documented on a Fusion FX7 system (Pierce, Erlangen, Germany). The following antibodies were used for western blotting: rabbit anti-PPCS (ab140626, 1:2000) purchased from Abcam (Cambridge, UK), mouse anti-Tubulin (T5168, 1:15000) purchased from Sigma-Aldrich (St. Louis, USA), and mouse anti-ATP5B (ab14748, 1:1000). HRP-conjugated secondary antibodies for western blot were obtained from Jackson ImmunoResearch Laboratories (USA) (1:15,000).

### **Measurement of Cellular CoA**

Total cellular CoA was measured using a fluorimetric-based kit (Abcam, ab138889) according to manufacturer instructions. Briefly,  $1 \times 10^6$  cells of fibroblasts, growing in exponential phase under standard medium (Dulbecco's Modified Eagle Medium High Glucose, 10% Fetal Bovine Serum, 4mM glutamine, 1% penicillin/streptomycin) were collected, and the pellet resuspended in 500 $\mu$ l of lysis buffer (Abcam, ab179835). After 15 minutes incubation at room temperature, cell debris was spun down by centrifugation at 1500 rpm for 5 minutes. For each measurement, 50 $\mu$ l of clear supernatant was used. A CoA standard curve was generated by plotting relative fluorescence values (RFU) and serial dilution of CoA standard. CoA levels in test samples were calculated by using the calibration curve. Results are mean  $\pm$  SD of n=16 values. *p*-values were calculated with an independent sample t-test. All *p*-values were two-sided with a significance level of 0.05.

#### **Serum Pantothenic Acid, PPCS and CoA Measurements**

Serum samples were obtained from individuals IV.1 and IV.4, family B, as well as from healthy controls. Pantothenic acid levels were measured at Mayo Medical Laboratories (Mayo Clinic). ELISA commercial kits (MBS283149, MYBioSource) were used for measurement of PPCS levels, and Coenzyme A detection kit (ab102504, Abcam) for measurement of CoA levels in serum.

#### ***Drosophila* Stocks and Cardiac Physiological Measurements**

In all experiments, we used *dPPCS* mutant flies carrying a P element insertion in the 5'-UTR of the gene, resulting in a lower expression of dPPCS protein. This mutant, indicated as *dPPCS<sup>1</sup>/TM3-GFP*, was extensively described in <sup>8</sup>. All flies were maintained at 25°C on standard medium. Heterozygous and homozygous pre-pupae were selected on the basis of GFP fluorescence (homozygous pre-pupae are GFP-negative). High-speed movies of spontaneous heart wall contractions in whole pre-pupae were recorded for 3x10 seconds at a rate of 100 frames per second by using a BlueFOX3 digital camera on a

Leica DM IL LED microscope with a 10x lens. Heart rate was manually analyzed with ImageJ. Kymographs were constructed using ImageJ and used to measure heart wall shortening, systolic and diastolic length. Arrhythmia index was obtained from a 2 minute/100 frames per second high-speed movie with a 20x lens of spontaneous heart wall contractions in whole pre-pupae and analyzed by via software as described before <sup>22</sup>.

### ***Drosophila* Viability and Pantethine Treatment**

Heterozygous males and females *dPPCS*<sup>1</sup>/TM3-GFP were transferred into vials and were allowed to produce embryos on control food, food containing 12 mM Vitamin B5 and food containing 8 mM pantethine, as previously described in <sup>23</sup>. After 5 days, adult flies were removed and after 12 days, the amount of homozygous and heterozygous pupae was determined.

### **Targeted Treatment with Pantethine in Affected Individuals**

After obtaining informed consent of the affected individuals or their parents, as well as institutional review board approval as compassionate treatment, the only two living affected individuals (IV.1 and IV.4, family B) commenced oral pantethine (Now Foods, Bloomingdale, IL, USA) supplementation at an initial dose of 6-8 mg/kg/day (once daily), which was subsequently gradually increased to 20-24 mg/kg/day.

## **RESULTS**

### **Molecular Diagnosis by Next Generation Sequencing**

In family A, a search for homozygous or potentially compound heterozygous non-synonymous rare variants with a minor allele frequency (MAF)<0.1% prioritized in the Munich in-house database,

containing 11.525 control exomes, rare variants in two genes, *PPCS* and *C4orf21*. Neither of these genes have so far been associated with human disease. Due to the function of the encoded protein and *in silico* prediction, we considered *PPCS* (NM\_024664.3) as the top candidate gene. In family B, a search for recessive inheritance, resulted in 26 genes harboring rare (MAF<0.01%) non-synonymous variants, for which the proband was homozygous and the mother heterozygous (Table S2). Further analysis excluded 21 variants (benign, reported in unaffected individuals, genes unrelated to the phenotype), resulting in 5 candidate genes. As 3 of these variants were located within introns, the remaining two (in *PPCS* and *PPID*) were further evaluated for segregation in the family. Finally, *PPCS*, which was not previously associated with a human phenotype however is known for its role in the CoA biosynthesis pathway, remained as the most promising candidate for further analysis.

Exome Sequencing in individual II.2 of family A, led to the identification of the heterozygous changes c.320\_334del (p.Pro107\_Ala111del) and c.538G>C (p.Ala180Pro) in *PPCS* (Figure 2B). Carrier testing confirmed that the variant c.320\_334del was located on the paternal and the variant c.538G>C on the maternal allele.

In family B, WES identified the homozygous c.698A>T mutation (p.Glu233Val) in exon 3 of the *PPCS* gene of individual IV.8 (Figure 2B). Segregation analysis in all available family members confirmed full segregation, with all four affected siblings found to harbor the c.178A>T mutation in homozygous form, both parents and two of the four unaffected siblings (subjects IV.2 and IV.7) found to be heterozygous for the mutation, and the remaining two unaffected siblings (subjects IV.3 and IV.6) found to be wild type.

None of the *PPCS* missense variants (c.698 A>T, c.538 G>C) are listed in the gnomAD (Genome Aggregation Database) browser (12/2017). The inframe deletion c.320\_334del is listed 10x only in a heterozygous state in 271,726 alleles of the gnomAD browser. No additional rare biallelic *PPCS* variants

were observed in the Munich in-house database containing exome dataset from more than 11,000 individuals with unrelated phenotypes.

### **Bioinformatic Analysis of the Variants Found in *PPCS***

The two SNV mutations p. Glu233Val and p. Ala180Pro (canonical isoform) are categorized as highly deleterious by almost all prediction tools (Table S1), including Polyphen, Sift, LRT, MutationTaster, MutationAssessor and Provean. These tools base their predictions on different considerations, but heavily rely on evolutionary conservation. Indeed, the mutated amino acids and their vicinity are conserved throughout evolution (Figure 2A). Mapping the conservation scores to the protein structure using ConSurf also reveals conserved structural cluster in the general region of the mutations (Figure S1A). These mutations are not likely to change drastically the protein stability as they are partially exposed to the surface and not integral part of the protein.

The two positions share several topological and structural commonalities. Residues Glu233 and Ala180 of *PPCS* have their side chain partially exposed to the surface (33% and 20% relative accessibility, respectively). Both are located within the core Coa-B like domain. The two positions are also spatially close and separated by only about 10 Å as indicated by the structure of the human protein which was resolved to 2.3 Å resolution (PDB 1P9O). Unfortunately, PDB file 1P9O does not contain ligands or cofactors, complicating the analysis of possible involvement of Ala180 and Glu233 in molecular binding. We thus attempted to examine additional related structures which include cofactors. A sensitive psi-blast sequence search identified the phosphopantothencysteine synthetase protein from *E. coli*, as a remote homolog of *PPCS* (20 % identity). This protein has been crystalized (PDB 1U7W) with a CTP nucleotide cofactor<sup>10</sup>. Structural alignment of 1P9O and 1U7W revealed a highly similar fold (Figure S1C) with the best alignment encompasses 159 residues with RMSD of 0.85 Å (p-value for structure similarity < E-15). Glu233 was found to be located in close vicinity to the phosphate recognition region of the

nucleotide binding site. This residue is conserved in the bacterial protein (residue Phe330 therein) in spite of low overall sequence similarity between the proteins. Phe330 creates contact with the CTP phosphate group in the bacterial protein. It is not entirely clear how the negatively charged residue creates favorable contacts with the negative phosphate. One option is that the recognition is mediated by a divalent cation. Indeed, the binding of the phosphate in the other side of the binding cleft is mediated by a positive calcium ion (Figure S1D) which is coordinated to a negatively charged aspartate (Asp276). It can well be that Phe330 also coordinates a mediator ion which was not resolved by the X-ray crystallography. The other option is that an electrostatic repulsive force helps to orientate the nucleotide in the binding site.

Ala180 is also located in the nucleotide binding cleft, but in a closer vicinity to the sugar moiety. The equivalent residue in the bacterial protein is Ala276, suggesting the need for a small residue at this spot.

The side chain in both the bacterial and human proteins point to the opposite side of the nucleotide.

Although the nucleotide involved in the human protein reaction is ATP and not CTP, still the phosphate and sugar binding mode are likely to be conserved as these parts are identical.

In conclusion, there is a consensus agreement regarding the deleterious effect of both p. Glu233Val and p. Ala180Pro on the protein function, which reflects the high evolutionary conservation of both sites.

The changes are likely to affect the binding to the ATP co-factor of PPCS.

The mutation c. 320\_334del affects a region which is not conserved in evolution (Figure 2A). However, prediction programs such as Mutation taster predict the change to be deleterious since the missing amino acids may be relevant to keep the conformation of the protein (Figure S1F). The human PPCS forms a dimer that is biologically relevant for function<sup>9; 10</sup>. The dimer has two dimerization regions including a non-conserved sequence between helices  $\alpha 4$  and  $\alpha 5$  (residues 107-111). In the crystal structure of human PPCS (PDB code 1P9O)<sup>9</sup>, these residues are intertwined in the other monomer,

although for part of them there is no electron density for residues 107-111 (marked in red in Figure S1G (zoom)).

Deletion of residues 107-111 could result in a destabilization of this dimerization region. In particular, it is possible that the deletion leads to a shortening of the strand  $\beta 5$  as seen in Figure S1F, G of the SWISS-MODEL model of the deletion mutant<sup>24-27</sup>. Additionally, the deletion could lead to rearrangement of helices  $\alpha 4$  and  $\alpha 5$  and dynamics of the protein, and eventually to change the substrate binding region.

### **Validation of Pathogenicity of Mutations in Yeast**

*yPPCS* is a gene essential for yeast viability<sup>6</sup>. In order to evaluate the functional relevance of identified *PPCS* variants, we performed a functional complementation of the *yPPCS* null background with the human wild type *PPCS* and its mutant variants using the method of plasmid shuffling<sup>28</sup>. The genuine *yPPCS* gene was used as positive control, while an empty vector was used as negative control.

As expected, transformants containing pGE12 (*LEU2 CAB2*) are able to grow while empty vector transformants fail to grow (Figure 4, lines 1 and 2, respectively). Importantly, expression of the cDNA of wild-type *hPPCS* in yeast restores growth even in the absence of *yPPCS*, although slightly less efficient than authentic *yPPCS* (line 3). In contrast, transformants with deletion or missense variants of *hPPCS* were unable to grow on 5-FOA-containing medium after two days of cultivation (lines 4-6). However, after four days mutant variants *hPPCS* 320\_334del (line 4) and *hPPCS* 698A>T (line 6) could support a minimal growth while variant *hPPCS* 538G>C (line 5) turned out to be completely non-functional even when the time of cultivation was extended.

### **Stability of PPCS Protein in Cells**

In order to gain insight on the effects of identified mutations on *PPCS* stability, we performed an immunoblotting analysis on fibroblasts extracts from the four affected individuals, three unrelated

controls, and one affected cell individual transduced with the wild-type *PPCS* cDNA (Figure 5A, Figure S3). Under denaturing conditions, the monoclonal PPCS antibody, directed against the C-terminal region present in both PPCS isoforms, detected both in control and affected individuals a main band of 34 kDa, corresponding to the canonical isoform. In subject II.2, family A (FA:II.2 in Figure 5A and Figure S3) there is a second band corresponding to the deletion-carrying allele, in addition to the 34kDa band, corresponding to the missense-carrying allele. The normalization of the signal of PPCS to the loading control  $\alpha$ -tubulin, revealed a marked reduction in PPCS levels in all affected individuals, with the strongest reduction observed in individual II.2 (Figure 5B and Figure S3). The expression of the wild type *PPCS* in the fibroblasts of individual II.2 (FA:II.2-T-PPCS in Figure 5A) normalized the PPCS protein levels (Figure 5B).

As the 320\_314del allele carried by individual II.2, family A was predicted to be associated with a dimerization defect, we performed an immunoblotting analysis under native conditions on fibroblasts extract from this subject to verify whether at least the missense allele could form a dimer (Figure 5C). The PPCS antibody detected one band of about 70 kDa in the cell extract from a healthy control (C1 in Figure 5C), corresponding to the expected size of a PPCS dimer (about 68 kDa). No signal was instead present in the cell extract of the affected individual (Figure 5C). This pointed out that either the proteins encoded by the deletion and missense alleles are extremely unstable and do not form a dimer, or if a dimer is made by the missense carrying protein, the level is so low that the antibody cannot detect it. We looked also for the monomeric PPCS in control and individual II.2, but in none of them the monomeric PPCS was detected, indicating that in physiological conditions PPCS exists mainly as a dimer.

### **Intracellular CoA levels in the Presence of *PPCS* Mutations**

To gain further insight into the impact of *PPCS* variants on the steady state level of CoA, we measured total cellular CoA levels in fibroblasts from all four *PPCS*-deficient individuals and compared this to the

levels of CoA in fibroblasts from a commercially available control (NDHFneo, C1) and two healthy controls (C2 and C3) (Figure 6). The investigation revealed a significant reduction of CoA in all four affected individuals, which was rescued by reintroducing the wild type copy of the gene (Figure 6).

### **Metabolic Investigation in Blood and Serum of *PPCS*-deficient Individuals**

Acylcarnitine profiles in dried blood spots of the probands revealed normal levels of free carnitine (C0) but relatively low concentrations of long chain acylcarnitines C16 and C18, leading to an elevated ratio  $C0/(C16+C18)$  and reduced ratio  $(C16+C18:1)/C0$  (Table 2).

Pantothenic acid (Vitamin B5) in the serum of available affected individuals (IV.1 and IV.4, family B) was within normal limits for both affected siblings (74.95  $\mu\text{g/L}$  and 73.84  $\mu\text{g/L}$ , respectively. Normal range for >10 years 37-147  $\mu\text{g/L}$ ).

Unfortunately, the levels of *PPCS* and CoA were consistently undetectable in both the affected and control samples.

### **Functional Metabolic Tests during Fasting**

Following the identification of pathogenic variants in *PPCS*, known to be involved in the CoA synthesis pathway, we sought to evaluate the Respiratory Quotient (RQ) and Basal Metabolic Rate (BMR) for the two live affected siblings (subjects IV.1 and IV.4, family B). This investigation (performed during fasting, at 21 years of age for individual IV.1 and at 9.5 years of age for individual IV.4) showed the RQ to be 0.773 and 0.796, respectively, both consistent with normal fat oxidation. BMR was found to be elevated for both siblings, 2771 kcal/day for individual IV.1 and 2091 kcal/day for individual IV.4, consistent with 142% and 160% of expected for their body weight and composition, respectively. This elevation was to be expected and indeed attributable to their current state of heart failure.

### **Homozygous *dPPCS*<sup>1</sup> Flies Show Altered Physiological Cardiac Parameters**

To examine the effect of the *dPPCS*<sup>1</sup> mutation on cardiac function, heart rate, arrhythmia index, heart wall shortening and systolic and diastolic length were determined in heterozygous and homozygous *dPPCS*<sup>1</sup> *Drosophila melanogaster*. In comparison with heterozygous *dPPCS*<sup>1</sup> flies, homozygous *dPPCS*<sup>1</sup> flies showed a significant increase in heart rate, heart wall shortening and arrhythmia index and a decrease in systolic length (Figure 7). These findings indicate that homozygous variants in *dPPCS* are associated with cardiac dysfunction in *Drosophila*.

### **Pantethine Supplementation in *Drosophila* with *dPPCS* Deficiency Improves Viability**

Based on Mendelian inheritance, the genotype of the F1 embryonal progeny of crossing *dPPCS*<sup>1</sup>/TM3-GFP adults is the following: 50% will be *dPPCS*<sup>1</sup>/TM3-GFP; 25% will be *dPPCS*<sup>1</sup>/*dPPCS*<sup>1</sup>; 25% will be TM3-GFP/TM3-GFP. The genotype TM3-GFP/TM3-GFP (homozygous for the balancer chromosome) induces a fully penetrant early developmental lethality and this genotype is not present in the F1 adult progeny, which therefore based on Mendelian inheritance consists of 66.6 % *dPPCS*<sup>1</sup>/TM3-GFP and 33,3 % *dPPCS*<sup>1</sup>/*dPPCS*<sup>1</sup> flies only. *dPPCS*<sup>1</sup>/*dPPCS*<sup>1</sup> homozygous adults are viable<sup>7; 8</sup>. The exact percentages of the two viable genotypes of the F1 are not only determined by Mendelian inheritance but can also be influenced by the impact of the *PPCS*<sup>1</sup> allele on viability. In the case a homozygous mutation in *dPPCS* negatively influencing viability, less than 33.3% of the F1 progeny will consist of *dPPCS*<sup>1</sup>/*dPPCS*<sup>1</sup> homozygous mutant flies. In our crosses, the percentage of homozygous *dPPCS*<sup>1</sup> pupae was ranged from 9 to 22%, suggesting a reduced viability in homozygous mutants. Pantethine can serve as a source for CoA *de novo* biosynthesis, since pantothenate kinase is the first enzyme of the canonical CoA biosynthesis pathway it can phosphorylate pantethine to form 4-phosphopantetheine<sup>29; 30</sup>. This route therefore does not require *PPCS*. Addition of pantethine to the fly food indeed rescued the percentage homozygous survivors to levels that can be expected based on Mendelian inheritance. Vitamin B5 was

used as a control. Experiments were repeated twice. In both experiments a rescue of 10% was observed (Figure S2).

### **Effects of Pantethine Supplementation in Individuals with *PPCS* Deficiency**

The two living affected individuals (IV.1 and IV.4, family B) commenced oral pantethine supplementation, initially at a dose of 6-8 mg/kg/day (once daily), which was subsequently gradually increased over a period of two months, reaching 20-24 mg/kg/day. At two months intervals, serial clinical evaluations, including pediatric cardiology visits and echocardiograms, and serum acylcarnitine profiles using dried blood spots were obtained (Table 2). Compared to their baseline evaluations, both clinical and echocardiographic evaluations had shown individual IV.1 to experience a mild improvement in exertional dyspnea and an increase of ejection fraction (EF, using the Simpson mode) from 36% (at baseline) to 48% (at a recent visit); subject IV.4 remained stable, with symptoms of heart failure upon exertion and an EF of 45%.

### **DISCUSSION**

Here, we report five individuals from unrelated families in whom biallelic mutations in *PPCS* lead to a cardiac phenotype. Variants identified in *PPCS*-deficient individuals are extremely rare. In our in-house database containing > 10,000 WES data sets we could not identify additional individuals carrying other rare biallelic *PPCS* variants. Moreover, in the gnomAD browser neither of the two missense variants are present either as homozygous or heterozygous variants. The inframe deletion is instead only present as a heterozygous variant with a MAF of 0.0001.

In addition to frequency considerations, identified variants are also predicted to be deleterious according to structural assumptions. In fact, mutations either change amino acids involved in the binding of ATP to *PPCS*, or amino acids relevant in humans for the dimerization of *PPCS*.

In order to verify the pathogenicity of identified variants, we utilised a yeast null mutant for *yPPCS*. It is known that ablation of *yPPCS* is lethal, therefore we investigated whether transforming the *yPPCS*-null mutant with the wild-type *PPCS* or variant-carrying *PPCS* constructs, could rescue the lethal phenotype. For validation experiments we considered the long canonical isoform NM\_024664.3 as the isoform associated with the pathology since the mutation p. Pro107\_Ala111del carried by subject II.2 of family A affects only this isoform.

While expression of the wild type *PPCS* complemented the lethal phenotype in the *yPPCS* deletion strain, a clear growth defect was observed for all strains transformed with the identified human variants, thus confirming their deleterious nature. c.538G>C in particular was completely inactive, indicating that this variant impairs *PPCS* function more dramatically than the other variants.

It is likely that the decreased enzymatic activity of *PPCS* is due to decreased protein stability, as indicated by the strong reduction of *PPCS* signal in all *PPCS*-deficient individuals in the western blotting experiment or by the inability to assemble into a functional *PPCS* dimer. Of note, the monoclonal *PPCS* antibody detected only one band of 34 KDa under denaturing conditions, despite the antibody's epitope residing within the C-terminus region, common to the two *PPCS* isoforms. The presence of a single band corresponding to the canonical isoform, suggests that this is likely the only splice variant translated into a protein.

In contrast to the neurodegenerative NBIA-related phenotypes associated with defects in *PANK2* and *COASY*, *PPCS*-deficient individuals present with a clear dilated cardiomyopathy with a variable degree of severity and no neurodegeneration. Only in one individual (II.2, family A) were extra-cardiac features present in addition to severe dilated cardiomyopathy. Presumably the presence of a completely inactive *PPCS* allele determines a more severe phenotype in this individual, as expected from the lack of rescue in yeast. Nonetheless no neurodegeneration was present.

In fruit flies, impairment of *dPPCS* is associated with neurological impairment. In view of the fact that *PPCS*-deficient individuals have dilated cardiomyopathy, we reinvestigated *dPPCS* mutants with a focus on cardiac function. With deeper inspection, *dPPCS* mutants presented with reduced viability, and moreover showed increased heart rate, increased arrhythmia index, reduced systolic function and increased heart wall shortening; all manifestations indicative of dilate cardiomyopathy in fruit flies <sup>31</sup>.

We therefore conclude that the cardiac phenotype of *dPPCS* flies recapitulates the pathophysiological alteration seen in *PPCS*-affected individuals, suggesting that alteration in *PPCS* can cause dilated cardiomyopathy.

In *Zebrafish* for instance, the down regulation of *pank2* leads to perturbation in the vasculature development, reduced heart beat and slower blood flux in addition to neurodegenerative signs <sup>32</sup>, while the down regulation of *coasy* leads to edema at a cardiac level <sup>33</sup>, suggesting already a link between CoA biosynthesis and cardiac function. With this knowledge in mind, it would be interesting to also investigate if fruit flies with *dPANK* and *dCOASY* impairment have a subtle cardiac dysfunction, accompanying the most obvious neurodegeneration.

*PPCS* is the second enzyme of the CoA de novo biosynthesis pathway. Mutations in enzymes taking part in the route are expected to result in reduced CoA biosynthesis. Indeed, in *PPCS*-deficient individuals the level of free CoA is significantly lower than in healthy controls. By reintroducing the wild type copy of the *PPCS* in fibroblasts of an affected individual the level of CoA is restored to normal values.

In contrast to *PPCS*-affected individuals, subjects with PKAN (Pantothenate Kinase-Associated Neurodegeneration) and COPAN (COASY protein-Associated Neurodegeneration) do not have detectable decrease of CoA levels in fibroblasts, despite the fact that most of the mutations in *PANK2* and *COASY*, impair the enzymatic activity of the recombinant enzymes respectively <sup>2, 34</sup>.

Explanations why mutations in *PPCS* do lead to decreased CoA levels in fibroblasts and mutations in *PANK2* and *COASY* do not show a decrease in CoA levels and how this is possibly linked to a cardiac

disease versus a neurodegenerative disease are currently not present. In order to understand these differences, CoA should be measured in relevant tissue of all conditions, meaning in the Globus Pallidus of PKAN and COPAN models and in cardiac tissue of PPCS-deficient models. Analysis of the abundance of PANK2, PPCS and COASY in relevant tissue, the identification of exact intracellular localizations of these three *de novo* CoA biosynthesis enzymes in disease affected tissues, elucidation of possible redundancies in their roles in CoA synthesis and identification of potential moonlighting functions are required to obtain answers to these intriguing questions.

Reduced cytosolic CoA concentration in PPCS-affected individuals may lead to a reduced synthesis of activated long chain fatty acids in *PPCS*-affected individuals. Therefore, there is only limited substrate for carnitine palmitoyltransferase I (CPT1), resulting in reduced long chain acylcarnitine concentrations, similar to individuals with carnitine palmitoyltransferase I (CPT1) deficiency. Indeed, this pattern is present in all individuals with PPCS deficiency, but not in the asymptomatic carrier (III.1) and has also been reported in two patients with COPAN<sup>5</sup>.

Since CoA has a pivotal role in heart metabolism, not only as a source of energy, but also as a modulator of fatty acid and glucose oxidation<sup>37</sup>, it is expected that alteration in CoA metabolism impair cardiac function.

We cannot exclude that cardiomyopathy in *PPCS*-deficient individuals is also due to the generation of toxic metabolites. For instance, L-cysteine normally funneled in the synthesis of phosphopantothienoylcysteine, could accumulate and eventually exceed the cytotoxicity threshold leading to detrimental effects in tissues, especially in the heart<sup>38</sup>. Consistent with this hypothesis, *dPPCS* mutants have been reported to be hypersensitive to cysteine<sup>8</sup>.

However, considering the ubiquitous presence of the enzymatic PPCS activity, it remains unexplained why the brain and in general the other organs are not affected in *PPCS*-deficient individuals.

Aside from this open question which future studies will address, the identification of *PPCS* variant as the causative mutation in families A and B, suggested a therapeutic trial of oral pantethine supplementation as targeted treatment aimed to bypass the deficient enzyme in the CoA synthesis pathway <sup>39</sup>. We treated *dPPCS* mutants with pantethine, and the compound successfully rescued the viability in homozygous mutants. These results are also consistent with studies performed in *PPCS* mutants in Bacteria <sup>30</sup>. Following the promising results from the *Drosophila* model, empirical targeted treatment with pantethine was introduced for the two living affected siblings of Family B. Our results thus far had not shown significant clinical improvement. This can be explained by the late introduction of the treatment in their clinical course, after cardiac damage had already occurred. Future studies, following early detection and initiation of treatment in additional affected families, may shed light on whether this therapeutic intervention can indeed bring more substantial clinical benefit, as demonstrated in the *Drosophila* model.

In summary, although the precise mechanism by which decreased CoA leads to cardiac rather than neurological problems remains to be fully elucidated, we demonstrate that pathogenic changes in *PPCS* lead to decreased CoA concentrations and cause cardiomyopathy with variable progression.

**Acknowledgement:** This study was supported by the German BMBF and Horizon2020 through E-Rare project GENOMIT (01GM1603 and 01GM1207 to HP); Horizon2020 Project SOUND (633974 to HP); German Network for Mitochondrial Disorders (mitoNET 01GM1113C to HP and TM); the German Center for Heart Research (Z76010017300 and Z56010015300 to TM). We thank Dr. Angelika Seitz (Department of Neuroradiology, University Hospital Heidelberg) for the interpretation of the cranial MRI of individual II.2, Family A, and Dr. Yussef Shahin who participates in the cardiology care of Family B. Shachar Abudi is an MD PhD student at the Sackler Faculty of Medicine, Tel-Aviv University, and a candidate for the

Graduate Partnership Program of the National Institutes of Health (NIH). The authors wish to thank the affected persons and their families for their continued support and collaboration. The authors declare no conflicts of interest.

## Web Resources

OMIM - Online Mendelian Inheritance in Man, <https://www.omim.org/>

The Human Protein Atlas, <https://www.proteinatlas.org/ENSG00000127125-PPCS/tissue>

GTEx Portal, <https://www.gtexportal.org/home/gene/PPCS#geneExpression>

Reactome, <https://reactome.org/content/detail/R-HSA-196772>

gnomAD, <http://gnomad.broadinstitute.org/>

## REFERENCES

1. Hartig, M.B., Hortnagel, K., Garavaglia, B., Zorzi, G., Kmiec, T., Klopstock, T., Rostasy, K., Svetel, M., Kostic, V.S., Schuelke, M., et al. (2006). Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. *Ann Neurol* 59, 248-256.
2. Dusi, S., Valletta, L., Haack, T.B., Tsuchiya, Y., Venco, P., Pasqualato, S., Goffrini, P., Tigano, M., Demchenko, N., Wieland, T., et al. (2014). Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. *Am J Hum Genet* 94, 11-22.
3. Hogarth, P. (2015). Neurodegeneration with brain iron accumulation: diagnosis and management. *J Mov Disord* 8, 1-13.
4. Annesi, G., Gagliardi, M., Iannello, G., Quattrone, A., Iannello, G., and Quattrone, A. (2016). Mutational analysis of COASY in an Italian patient with NBIA. *Parkinsonism Relat Disord* 28, 150-151.
5. Evers, C., Seitz, A., Assmann, B., Opladen, T., Karch, S., Hinderhofer, K., Granzow, M., Paramasivam, N., Eils, R., Diessl, N., et al. (2017). Diagnosis of CoPAN by whole exome sequencing: Waking up a sleeping tiger's eye. *Am J Med Genet A*.
6. Olzhausen, J., Schubbe, S., and Schuller, H.J. (2009). Genetic analysis of coenzyme A biosynthesis in the yeast *Saccharomyces cerevisiae*: identification of a conditional mutation in the pantothenate kinase gene CAB1. *Curr Genet* 55, 163-173.
7. Bosveld, F., Rana, A., Lemstra, W., Kampinga, H.H., and Sibon, O.C. (2008). *Drosophila* phosphopantothenoylcysteine synthetase is required for tissue morphogenesis during oogenesis. *BMC Res Notes* 1, 75.

8. Bosveld, F., Rana, A., van der Wouden, P.E., Lemstra, W., Ritsema, M., Kampinga, H.H., and Sibon, O.C. (2008). De novo CoA biosynthesis is required to maintain DNA integrity during development of the *Drosophila* nervous system. *Hum Mol Genet* 17, 2058-2069.
9. Manoj, N., Strauss, E., Begley, T.P., and Ealick, S.E. (2003). Structure of human phosphopantothenoylcysteine synthetase at 2.3 Å resolution. *Structure* 11, 927-936.
10. Stanitzek, S., Augustin, M.A., Huber, R., Kupke, T., and Steinbacher, S. (2004). Structural basis of CTP-dependent peptide bond formation in coenzyme A biosynthesis catalyzed by *Escherichia coli* PPC synthetase. *Structure* 12, 1977-1988.
11. Berman, H.M., Westbrook, J.D., Gabanyi, M.J., Tao, W., Shah, R., Kouranov, A., Schwede, T., Arnold, K., Kiefer, F., Bordoli, L., et al. (2009). The protein structure initiative structural genomics knowledgebase. *Nucleic Acids Res* 37, D365-368.
12. Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D.J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res* 25, 3389-3402.
13. Nussinov, R., and Wolfson, H.J. (1991). Efficient detection of three-dimensional structural motifs in biological macromolecules by computer vision techniques. *Proc Natl Acad Sci U S A* 88, 10495-10499.
14. Solomon, O., Kunik, V., Simon, A., Kol, N., Barel, O., Lev, A., Amariglio, N., Somech, R., Rechavi, G., and Eyal, E. (2016). G23D: Online tool for mapping and visualization of genomic variants on 3D protein structures. *BMC Genomics* 17, 681.
15. Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., and Ferrin, T.E. (2004). UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* 25, 1605-1612.
16. Fraczekwicz, R., and Braun, W. (1998). Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules. *Journal of Computational Chemistry* 19, 319-333.
17. Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., and Ben-Tal, N. (2016). ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. *Nucleic Acids Res* 44, W344-350.
18. Yang, J., Roy, A., and Zhang, Y. (2013). Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment. *Bioinformatics* 29, 2588-2595.
19. Roy, A., Kucukural, A., and Zhang, Y. (2010). I-TASSER: a unified platform for automated protein structure and function prediction. *Nature protocols* 5, 725-738.
20. Kremer, L.S., and Prokisch, H. (2017). Identification of Disease-Causing Mutations by Functional Complementation of Patient-Derived Fibroblast Cell Lines. *Methods Mol Biol* 1567, 391-406.
21. Mumberg, D., Muller, R., and Funk, M. (1994). Regulatable promoters of *Saccharomyces cerevisiae*: comparison of transcriptional activity and their use for heterologous expression. *Nucleic Acids Res* 22, 5767-5768.
22. Nolte, I.M., Munoz, M.L., Tragante, V., Amare, A.T., Jansen, R., Vaez, A., von der Heyde, B., Avery, C.L., Bis, J.C., Dierckx, B., et al. (2017). Erratum: Genetic loci associated with heart rate variability and their effects on cardiac disease risk. *Nat Commun* 8, 16140.
23. Rana, A., Seinen, E., Siudeja, K., Muntendam, R., Srinivasan, B., van der Want, J.J., Hayflick, S., Reijngoud, D.J., Kayser, O., and Sibon, O.C. (2010). Pantethine rescues a *Drosophila* model for pantothenate kinase-associated neurodegeneration. *Proc Natl Acad Sci U S A* 107, 6988-6993.
24. Biasini, M., Bienert, S., Waterhouse, A., Arnold, K., Studer, G., Schmidt, T., Kiefer, F., Gallo Cassarino, T., Bertoni, M., Bordoli, L., et al. (2014). SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. *Nucleic Acids Res* 42, W252-258.

25. Kiefer, F., Arnold, K., Kunzli, M., Bordoli, L., and Schwede, T. (2009). The SWISS-MODEL Repository and associated resources. *Nucleic Acids Res* 37, D387-392.
26. Arnold, K., Bordoli, L., Kopp, J., and Schwede, T. (2006). The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. *Bioinformatics* 22, 195-201.
27. Guex, N., Peitsch, M.C., and Schwede, T. (2009). Automated comparative protein structure modeling with SWISS-MODEL and Swiss-PdbViewer: a historical perspective. *Electrophoresis* 30 Suppl 1, S162-173.
28. Sikorski, R.S., and Boeke, J.D. (1991). In vitro mutagenesis and plasmid shuffling: from cloned gene to mutant yeast. *Methods in enzymology* 194, 302-318.
29. Sibon, O.C., and Strauss, E. (2016). Coenzyme A: to make it or uptake it? *Nat Rev Mol Cell Biol* 17, 605-606.
30. Balibar, C.J., Hollis-Symynkywicz, M.F., and Tao, J. (2011). Pantethine rescues phosphopantothenoylcysteine synthetase and phosphopantothenoylcysteine decarboxylase deficiency in *Escherichia coli* but not in *Pseudomonas aeruginosa*. *J Bacteriol* 193, 3304-3312.
31. Taghli-Lamalle, O., Akasaka, T., Hogg, G., Nudel, U., Yaffe, D., Chamberlain, J.S., Ocorr, K., and Bodmer, R. (2008). Dystrophin deficiency in *Drosophila* reduces lifespan and causes a dilated cardiomyopathy phenotype. *Aging Cell* 7, 237-249.
32. Zizioli, D., Tiso, N., Guglielmi, A., Saraceno, C., Busolin, G., Giuliani, R., Khatri, D., Monti, E., Borsani, G., Argenton, F., et al. (2016). Knock-down of pantothenate kinase 2 severely affects the development of the nervous and vascular system in zebrafish, providing new insights into PKAN disease. *Neurobiol Dis* 85, 35-48.
33. Khatri, D., Zizioli, D., Tiso, N., Facchinello, N., Vezzoli, S., Gianoncelli, A., Memo, M., Monti, E., Borsani, G., and Finazzi, D. (2016). Down-regulation of coasy, the gene associated with NBIA-VI, reduces Bmp signaling, perturbs dorso-ventral patterning and alters neuronal development in zebrafish. *Sci Rep* 6, 37660.
34. Kotzbauer, P.T., Truax, A.C., Trojanowski, J.Q., and Lee, V.M. (2005). Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. *J Neurosci* 25, 689-698.
35. Garcia, M., Leonardi, R., Zhang, Y.M., Rehg, J.E., and Jackowski, S. (2012). Germline deletion of pantothenate kinases 1 and 2 reveals the key roles for CoA in postnatal metabolism. *PLoS one* 7, e40871.
36. Fiermonte, G., Paradies, E., Todisco, S., Marobbio, C.M., and Palmieri, F. (2009). A novel member of solute carrier family 25 (SLC25A42) is a transporter of coenzyme A and adenosine 3',5'-diphosphate in human mitochondria. *J Biol Chem* 284, 18152-18159.
37. Abo Alrob, O., and Lopaschuk, G.D. (2014). Role of CoA and acetyl-CoA in regulating cardiac fatty acid and glucose oxidation. *Biochem Soc Trans* 42, 1043-1051.
38. Stipanuk, M.H., Dominy, J.E., Jr., Lee, J.I., and Coloso, R.M. (2006). Mammalian cysteine metabolism: new insights into regulation of cysteine metabolism. *J Nutr* 136, 1652S-1659S.
39. Srinivasan, B., Baratashvili, M., van der Zwaag, M., Kanon, B., Colombelli, C., Lambrechts, R.A., Schaap, O., Nollen, E.A., Podgorsek, A., Kosec, G., et al. (2015). Extracellular 4'-phosphopantetheine is a source for intracellular coenzyme A synthesis. *Nat Chem Biol* 11, 784-792.

**Table 1.** Demographic, clinical and molecular findings in individuals with mutations in *PPCS* (labelled as FB:IV.1, FB:IV.4, FB:IV.6, FB:IV.8, and FA:II.2 in the table).

Individual	FB:IV.1	FB:IV.4	FB:IV.6	FB:IV.8	FA:II.2
Gender	M	M	F	M	F
Ethnic background	Arab-Muslim	Arab-Muslim	Arab-Muslim	Arab-Muslim	Central Europe
Consanguinity	Yes	Yes	Yes	Yes	No
Dysmorphic features	No	No	No	No	Yes
Age at presentation	2 years	4 months	23 months	3 years	2 weeks
Cardiac manifestations	Dilated cardiomyopathy	Dilated cardiomyopathy	Severe dilated cardiomyopathy	Severe dilated cardiomyopathy	Severe dilated cardiomyopathy
Muscular hypotonia	No	No	N/D	N/D	Severe
Extracardiac manifestations	None	None	None	None	Yes
Serum lactate	Normal	Normal	Elevated	Elevated	Elevated
Status	Alive	Alive	Death at 23 months from	Death at 3 years from	Death at 3 months from DCM and multi

			DCM	DCM	organ failure
Brain MRI	Normal	N/D	N/D	N/D	Normal
Mutation in <i>PPCS</i>	c.[698A>T]; [698A>T]	c.[698A>T]; [698A>T]	c.[698A>T]; [698A>T]	c.[698A>T]; [698A>T]	c.[538G>C]; [320_334del]

N/D- no data available

**Table 2.** Acylcarnitine profiles in individuals with mutations in *PPCS* (FA:II.2, FB:IV.1, FB:IV.4, and FB:III.1 in the table) before and during panthetine supplementation.

Individual	Contr ols	FA:II.2	FB:IV.1				FB:IV.4				FB:III.1
<b>Genotype</b>		c.[538G>C];[320_334del]	c.[698A>T];[698A>T]				c.[698A>T];[698A>T]				c.[698A>T];[=]
<b>Pantethine Supplemen tation</b>		no	no	600 mg/ d	1800 mg/d	?	no	300 mg/ d	900 mg/ d	?	no
<b>C0</b>	6-65	30	42	45	44.5	38. 5	46	39	44	42	22.5
<b>C16</b>	0,79-	0,67	1.2	1.85	1.17	1.5	1.3	0.95	1.1	1.1	0.95

	5,72		1			6	3			2	
<b>C18</b>	0,38- 1,78	0,33	0.7 1	0.68	0.43	0.5 9	0.6	0.46	0.46	0.5 6	0.47
<b>C18:2</b>	0- 0,49	0,11	0.4 6	0.65	0.63	0.5 6	0.5 4	0.49	0.39	0.4 7	0.43
<b>C0/(C16+C18)</b>	2,30- 18	30	21. 88	17.7 9	27.81	17. 91	23. 83	27.6 6	28.2 1	25. 00	15.85
<b>(C16+C18:1)/C0</b>	0,08- 0,42	0,04	0.0 5	0.07	0.05	0.0 7	0.0 7	0.07	0.07	0.0 7	0.07

**Figure 1. Universal pathway for the biosynthesis of coenzyme A and associated diseases.** In green are indicated genes encoding either cytosolic or mitochondrial isoforms. The mitochondrial isoforms are associated with neurodegeneration with brain iron accumulation (#234200, #615643). In grey are labelled genes predicted to have mostly a cytosolic localization. The asterisk (\*) indicates that the association with a disease was not reported elsewhere.

**Figure 2. Structure of *PPCS* and Pedigrees of Investigated Families.** (A) Structure of *PPCS* with known conserved protein domain in the gene product and localization and conservation of amino acid residues affected by mutations identified in the two families. Intronic regions are not drawn to scale. Coloring in the sequence alignment represents the identity of amino acid residues. (B) Pedigrees of two families with mutations in *PPCS*. Mutation status of affected (closed symbols) and healthy (open symbols) family members. n.d. not determined.

**Figure 3. Cardiac Magnetic Resonance Imaging (cMRI) findings in individuals with *PPCS*-related dilated cardiomyopathy.** A) Four chamber view of individual IV.1 (FB:IV.1 in the figure) at the age of 21 years in diastole (Ai) and systole (Aii). Note the decreased change in ventricular volume between phases. RA-right atrium, LA-left atrium, RV-right ventricle, LV-left ventricle. B) Short axis oblique of individual IV.4 (at the age of 10 years) in diastole (Bi) and systole (Bii), consistent with a low cardiac output. C) Volume rendering of gadolinium-enhanced angiography of the chest and head blood vessels in individual IV.4 (posterior view), demonstrating normal vasculature.

**Figure 4. Functional complementation of a yeast *cab2* deletion mutation by human *PPCS* gene variants.** Strain MGY9, used as a recipient for transformation, contains a chromosomal *cab2* null mutation which was complemented by the single-copy URA3 *CAB2* plasmid pGE11. Single-copy LEU2 plasmids used for complementation studies contain yeast *CAB2* (positive control) and human *PPCS* alleles (wild-type and variants c.320\_334del, c.538G>C, c.698A>T). Transformants containing two autonomously replicating plasmids are shown (left, SCD-Ura-Leu. incubation for 2 days). To counter-select URA3 plasmid pGE11, transformants were transferred to a medium supplemented with 5-FOA and incubated for 2 or 4 days (middle, right).

**Figure 5. Western Blot analysis of *PPCS* protein in *PPCS*-mutant fibroblasts.** (A) Western blot analysis of fibroblasts from the four affected individuals (FA:II.2, FB:IV.8, FB:IV.4, FB:IV.1), one healthy control (C1) and from individual II.2, family A complemented by lentiviral transduction with wild-type *PPCS*. 7.5 and 15  $\mu$ g proteins were loaded.  $\beta$ -tubulin was used as a loading control. (B) Densitometric analysis of this western blot. Error bars indicate the standard error of the mean. (C) Blue native gel electrophoresis of total cellular extract from individual II.2, family A, and control C1 solubilized by 1% laurylmaltoside. ATP5 $\alpha$ ,  respiratory chain complex V, was used as a loading control

**Figure 6. Total cellular CoA in fibroblasts.** Fibroblasts growing in exponential phase under standard medium are collected, homogenized, and evaluated for CoA content. Relative fluorescence values (RFU) of serial dilution of CoA standard were measured to generate a calibration curve. CoA levels in fibroblasts were calculated by making use of the calibration curve. Fibroblasts from three unrelated controls (C1, C2, C3 in the figure) and from an affected individual transduced with wild-type *PPCS* (FA:II.2-T-PPCS) are labeled in blue; affected individuals (FA:II.2, FB:IV.1, FB:IV.4, FB:IV.8) are labeled in red. Results are mean  $\pm$  SD of n=16 values. *p*-values were calculated with an independent sample t-test. All *p*-values were two-sided with a significance level of 0.05.

**Figure 7. Physiological cardiac parameters are changed in homozygous *dPPCS*<sup>1</sup> *Drosophila melanogaster*.** A) Heart rate in beats per minute, B) arrhythmia index, C) systolic and D) diastolic length in seconds, E) heart wall shortening and F) representative kymographs (10 seconds). \*\* $P \leq 0.01$  and \*\*\* $P \leq 0.001$ . (N=50 for heterozygous and N=36 for homozygous for A and B; N=18 for heterozygous and N=15 for homozygous for C, D and E).

**Movie S1.** Three-dimensional volume rendering of gadolinium-enhanced angiography of the chest and head blood vessels in individual IV.4, family B, demonstrating normal vasculature.